e-learning
resources
Conferences
Lung Science Conference
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Oral presentation: Mesenchymal stem cells reduce lung metastases by controlled targeted delivery of TNF-related apoptosis-inducing ligand (TRAIL)
M. R. Loebinger, S.M. Janes (London, United Kingdom)
Source:
Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis
Number:
20
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. R. Loebinger, S.M. Janes (London, United Kingdom). Oral presentation: Mesenchymal stem cells reduce lung metastases by controlled targeted delivery of TNF-related apoptosis-inducing ligand (TRAIL). Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Mesenchymal stem cells reduce lung metastases by controlled targeted delivery of TNF-related apoptosis-inducing ligand (TRAIL)
Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer
Year: 2009
Effects of chemotherapeutic drugs and TRAIL (tumor necrosis factor-related apoptosis inducing ligand) on the non-small lung cancer cells
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
The role of TNF-related apoptosis inducing ligand (TRAIL) in fibrotic lung disease
Source: Annual Congress 2011 - Growth factors and fibrogenesis: are they good, bad or both?
Year: 2011
Role of TNF-related apoptosis inducing ligand (TRAIL) in lung protective immunity against
S. pneumoniae
Source: Annual Congress 2010 - Mechanisms of respiratory infections
Year: 2010
Alveolar recruited macrophages contribute to lung epithelial apoptosis and barrier dysfunction by expression of TNF-related apoptosis-inducing ligand during influenza virus pneumonia
Source: Annual Congress 2008 - Border patrol: the alveolar barrier in lung injury
Year: 2008
Macrophage released TNF-related apoptosis-inducing ligand (TRAIL) impairs alveolar fluid clearance after Influenza A virus infection
Source: Lung Science Conference 2015
Year: 2015
Gemcitabine sensitizes lung cancer cells to Fas /Fas ligand system-mediated killing
Source: Annual Congress 2011 - Treatment of lung cancer
Year: 2011
Mesenchymal stem cell based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysacharride in mice
Source: Annual Congress 2008 - Border patrol: the alveolar barrier in lung injury
Year: 2008
Inhibition of proliferation of lung cancer cells by CD40 signaling through tumor necrosis factor I
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
Inhibition of the effect of epidermal growth factor (EGF) on lung cancer cells. The use of plasmids encoding specific siRNA molecules
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
Enhanced expression of Fas ligand (FasL) in fibrotic interstitial lung diseases (ILDs). The possible role of membrane-bound FasL form
Source: Annual Congress 2011 - Genetic and molecular background in pulmonary fibrosis
Year: 2011
Multipotent stromal cell-derived stanniocalcin-1 reduces reactive oxygen species and promotes survival of injured A549 lung cancer cells through upregulation of uncoupling-protein 2 and induction of the Warburg effect
Source: Annual Congress 2010 - New insights into reactive oxygen species
Year: 2010
Contribution of genetic polymorphism of stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, to the susceptibility and severity of non-small cell lung cancer
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
LSC 2012 abstract – Effects of the Hedgehog (Hh) pathway inhibitor GDC-0449 on lung cancer cells and cisplatin resistant lung cancer cells are mediated by lung cancer stem cells (SPs)
Source: Annual Congress 2012 - New insights in the pathology of lung cancer
Year: 2012
Mesenchymal stromal (stem) cell therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury
Source: Eur Respir J, 59 (1) 2004216; 10.1183/13993003.04216-2020
Year: 2022
The death receptor Fas in CD3+T cells in patients with non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 673s
Year: 2004
NKG2D mediated cytotoxicity towards respiratory epithelial cells suggests a mechanism for lung injury following allogeneic stem cell transplantation
Source: Annual Congress 2007 - Epithelial networks in the airways
Year: 2007
Mesenchymal stem cells reduce hypoxia-induced apoptosis in alveolar epithelial cells by modulating hypoxic signaling
Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease
Year: 2015
Fas Ligand (FasL) expressed on alveolar lymphocytes (AL) plays role in progression of interstitial lung diseases (ILD) but not in local induction of immune cells apoptosis
Source: Eur Respir J 2005; 26: Suppl. 49, 542s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept